ABSTRACT
PURPOSE: The purpose of this study was to estimate markers of immunological response in the blood of children with intermediate uveitis. MATERIAL AND METHODS: The records of 13 children (26 eyes), aged 10-17 years, with idiopathic intermediate uveitis were reviewed. In all cases indicators of inflammation and immunological response parameters were analyzed during the active stage of the disease. RESULTS: In almost all patients ((90%) with intermediate uveitis disturbances in the level and activity of lymphocyte system, were detected. There were also nonspecific changes in immunoglobulins level in all patients, in 31% in more then one class of immunoglobulins. Chemiluminescence of phagocytic cells were reduced in more than 50% of children, and increase in their phagocytic activity was observed in 62% of patients. Circulating immune complexes were present in 50% of cases. CONCLUSIONS: The study presents data supporting the theory of autoimmunological background of the intermediate uveitis.
Subject(s)
Autoantibodies/blood , Uveitis, Intermediate/immunology , Uveitis, Intermediate/therapy , Adolescent , Antigen-Antibody Complex/blood , Biomarkers , Child , Complement System Proteins/analysis , Female , Follow-Up Studies , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Retrospective StudiesABSTRACT
The aim of the study was to analyze the clinical course and therapy in patients with differentiated thyroid carcinoma (DTC) diagnosed in Poland within the year 1995. The group of 478 patients with thyroid cancer (57.7% of all thyroid cancer cases diagnosed this year in Poland) was analyzed. Patients were diagnosed or treated in Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch. Detailed analysis was performed in 352 patients with DTC who were treated by surgery. 292 patients (60%) received adjuvant radioiodine therapy. Hormonal (L-thyroxine) treatment was administered to all patients. In 37 patients (8.6%) local recurrence was observed. 10-year overall survival was 96.4% and disease-free survival was respectively 68%. The comparison of Polish data to analysis in German population published by Holtzer et al. (Cancer, 2000) was also performed in this study. We conclude that DTC therapy, currently recommended in our country, gives satisfactory results and that clinical outcome and therapeutic methods are similar both in Poland and Germany.
Subject(s)
Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Thyroid Neoplasms/pathology , Thyroid Neoplasms/therapy , Adenocarcinoma, Follicular/pathology , Adenocarcinoma, Follicular/therapy , Adult , Antineoplastic Agents/therapeutic use , Carcinoma, Papillary/pathology , Carcinoma, Papillary/therapy , Chemotherapy, Adjuvant/statistics & numerical data , Disease-Free Survival , Female , Follow-Up Studies , Humans , Iodine Radioisotopes/therapeutic use , Male , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/surgery , Poland/epidemiology , Radiotherapy, Adjuvant/statistics & numerical data , Regression Analysis , Retrospective Studies , Survival Analysis , Thyroid Neoplasms/drug therapy , Thyroid Neoplasms/epidemiology , Thyroid Neoplasms/surgery , Thyroidectomy/statistics & numerical dataABSTRACT
We sought to evaluate the efficacy, biochemical effects, safety and outcome of recombinant human thyroid-stimulating hormone (rhTSH) as an adjunct to radioiodine treatment of advanced differentiated thyroid carcinoma (DTC). We also sought to determine whether rhTSH is useful as an adjunct to radioiodine treatment following isotretinoin re-differentiation therapy of DTC metastases that have lost function. Therefore, in 54 consecutive patients who had retained bulky metastatic and/or locoregional lesions of DTC despite the exhaustion of other therapeutic options, we gave one to four courses of two consecutive daily intramuscular injections of rhTSH, 0.9 mg, followed by a therapeutic activity of (131)I per os on day 3. Fifty patients had received prior radioiodine treatment aided by l-thyroxine (T(4)) withdrawal. We included in the study 23 patients who had received a trial of isotretinoin therapy for re-differentiation of confirmed de-differentiated metastases. In a blinded, within-patient comparison of post-therapy whole-body scans after the first rhTSH-aided and latest withdrawal-aided treatments in patients with functional metastases at baseline, 18 of 27 (67%) scan pairs were concordant, four (15%) were discordant in favour of the rhTSH-aided scan and five (19%) were discordant in favour of the withdrawal-aided scan. In total, 37 (74%) of 50 paired scans were concordant, eight (16%) favoured rhTSH and five (10%) favoured withdrawal. All differences appeared to be attributable to clinical causes, not to any difference between endogenous and exogenous TSH stimulation. Reflecting the biochemical activity of rhTSH and the release of thyroglobulin (Tg) due to tumour destruction, median serum Tg concentration rose approximately fourfold between baseline and day 6 of the rhTSH-aided treatment course. rhTSH was well tolerated, with mostly minor, transient toxicity, except for neck oedema in three patients with neck infiltrates and pathological spine fracture in one patient with a large vertebral metastasis. At 6 months, complete response occurred in one (2%), partial response in 12 (26%) and disease stabilisation in 19 (40%) of 47 evaluable patients. The rate of complete + partial response was 41% and that of disease stabilisation, 30%, in the 27 evaluable patients with functional metastases at baseline; the corresponding rates were 10% and 55% in the 20 evaluable patients with non-functional metastases at baseline. Although within-patient comparison of early outcome after both modalities is limited by a significantly greater median number of courses and a greater median cumulative activity of radioiodine given under withdrawal, response to rhTSH-aided and withdrawal-aided treatment was similar in 23 (52%) of 44 evaluable patients, superior with rhTSH in 12 (27%) and superior with withdrawal in seven (16%). In two patients, a superior response was obtained after isotretinoin pretreatment and rhTSH and attributed to re-differentiation therapy. In conclusion, our study provides preliminary evidence that rhTSH safely and effectively aids radioiodine treatment of advanced DTC, and does so to an at least equivalent degree as does T(4) withdrawal.